- Home
- ORKA vs AMAL Comparison
ORKA vs AMAL Comparison
Compare ORKA & AMAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- AMAL
- Stock Information
- Founded
- ORKA 2004
- AMAL 1923
- Country
- ORKA United States
- AMAL United States
- Employees
- ORKA N/A
- AMAL 429
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AMAL Commercial Banks
- Sector
- ORKA Health Care
- AMAL Finance
- Exchange
- ORKA Nasdaq
- AMAL Nasdaq
- Market Cap
- ORKA 580.3M
- AMAL 858.7M
- IPO Year
- ORKA N/A
- AMAL 2018
- Fundamental
- Price
- ORKA $15.08
- AMAL $28.17
- Analyst Decision
- ORKA Strong Buy
- AMAL Hold
- Analyst Count
- ORKA 8
- AMAL 2
- Target Price
- ORKA $40.43
- AMAL $33.00
- AVG Volume (30 Days)
- ORKA 136.9K
- AMAL 154.7K
- Earning Date
- ORKA 11-12-2025
- AMAL 10-23-2025
- Dividend Yield
- ORKA N/A
- AMAL 1.96%
- EPS Growth
- ORKA N/A
- AMAL 3.73
- EPS
- ORKA N/A
- AMAL 3.34
- Revenue
- ORKA N/A
- AMAL $304,724,000.00
- Revenue This Year
- ORKA N/A
- AMAL $9.82
- Revenue Next Year
- ORKA N/A
- AMAL $11.11
- P/E Ratio
- ORKA N/A
- AMAL $8.54
- Revenue Growth
- ORKA N/A
- AMAL 4.35
- 52 Week Low
- ORKA $5.49
- AMAL $25.03
- 52 Week High
- ORKA $31.13
- AMAL $38.19
- Technical
- Relative Strength Index (RSI)
- ORKA 49.99
- AMAL 40.94
- Support Level
- ORKA $15.23
- AMAL $28.32
- Resistance Level
- ORKA $16.21
- AMAL $29.19
- Average True Range (ATR)
- ORKA 0.94
- AMAL 0.59
- MACD
- ORKA -0.05
- AMAL -0.01
- Stochastic Oscillator
- ORKA 29.53
- AMAL 0.00
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.